298 related articles for article (PubMed ID: 9338007)
1. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.
Lemmon MJ; van Zijl P; Fox ME; Mauchline ML; Giaccia AJ; Minton NP; Brown JM
Gene Ther; 1997 Aug; 4(8):791-6. PubMed ID: 9338007
[TBL] [Abstract][Full Text] [Related]
2. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
[TBL] [Abstract][Full Text] [Related]
3. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.
Liu SC; Minton NP; Giaccia AJ; Brown JM
Gene Ther; 2002 Feb; 9(4):291-6. PubMed ID: 11896468
[TBL] [Abstract][Full Text] [Related]
4. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.
Fox ME; Lemmon MJ; Mauchline ML; Davis TO; Giaccia AJ; Minton NP; Brown JM
Gene Ther; 1996 Feb; 3(2):173-8. PubMed ID: 8867865
[TBL] [Abstract][Full Text] [Related]
5. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors.
Yazawa K; Fujimori M; Amano J; Kano Y; Taniguchi S
Cancer Gene Ther; 2000 Feb; 7(2):269-74. PubMed ID: 10770636
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF
Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508
[TBL] [Abstract][Full Text] [Related]
7. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
Palmer DH; Mautner V; Mirza D; Oliff S; Gerritsen W; van der Sijp JR; Hubscher S; Reynolds G; Bonney S; Rajaratnam R; Hull D; Horne M; Ellis J; Mountain A; Hill S; Harris PA; Searle PF; Young LS; James ND; Kerr DJ
J Clin Oncol; 2004 May; 22(9):1546-52. PubMed ID: 15051757
[TBL] [Abstract][Full Text] [Related]
8. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.
Bilsland AE; Anderson CJ; Fletcher-Monaghan AJ; McGregor F; Evans TR; Ganly I; Knox RJ; Plumb JA; Keith WN
Oncogene; 2003 Jan; 22(3):370-80. PubMed ID: 12545158
[TBL] [Abstract][Full Text] [Related]
9. [Hypoxia in malignant tumors the target for clostridial therapeutic gene strategies].
Wallner G; Misiuna P; Cygan W; Cygan Z
Pol Merkur Lekarski; 2005 Aug; 19(110):242-4. PubMed ID: 16245444
[TBL] [Abstract][Full Text] [Related]
10. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.
Plumb JA; Bilsland A; Kakani R; Zhao J; Glasspool RM; Knox RJ; Evans TR; Keith WN
Oncogene; 2001 Nov; 20(53):7797-803. PubMed ID: 11753658
[TBL] [Abstract][Full Text] [Related]
11. Suicide gene therapy using E. coli beta-galactosidase.
Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
[TBL] [Abstract][Full Text] [Related]
12. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
Bailey SM; Knox RJ; Hobbs SM; Jenkins TC; Mauger AB; Melton RG; Burke PJ; Connors TA; Hart IR
Gene Ther; 1996 Dec; 3(12):1143-50. PubMed ID: 8986441
[TBL] [Abstract][Full Text] [Related]
13. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
Drabek D; Guy J; Craig R; Grosveld F
Gene Ther; 1997 Feb; 4(2):93-100. PubMed ID: 9081711
[TBL] [Abstract][Full Text] [Related]
14. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
McNeish IA; Green NK; Gilligan MG; Ford MJ; Mautner V; Young LS; Kerr DJ; Searle PF
Gene Ther; 1998 Aug; 5(8):1061-9. PubMed ID: 10326029
[TBL] [Abstract][Full Text] [Related]
15. High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue.
Lipinski KS; Djeha AH; Ismail T; Mountain A; Young LS; Wrighton CJ
Mol Ther; 2001 Oct; 4(4):365-71. PubMed ID: 11592840
[TBL] [Abstract][Full Text] [Related]
16. Clostridia in cancer therapy.
Minton NP
Nat Rev Microbiol; 2003 Dec; 1(3):237-42. PubMed ID: 15035028
[TBL] [Abstract][Full Text] [Related]
17. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ
Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484
[TBL] [Abstract][Full Text] [Related]
18. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
19. Clostridium as a tumor-specific delivery system of therapeutic proteins.
Theys J; Landuyt AW; Nuyts S; Van Mellaert L; Lambin P; Anné J
Cancer Detect Prev; 2001; 25(6):548-57. PubMed ID: 12132875
[TBL] [Abstract][Full Text] [Related]
20. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
Chen MJ; Green NK; Reynolds GM; Flavell JR; Mautner V; Kerr DJ; Young LS; Searle PF
Gene Ther; 2004 Jul; 11(14):1126-36. PubMed ID: 15164095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
